Ovid Therapeutics

Yahoo Finance • last year

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026 Clinical trials study... Full story

Yahoo Finance • last year

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously reta... Full story

Yahoo Finance • last year

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today anno... Full story

Yahoo Finance • last year

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today ann... Full story

Yahoo Finance • last year

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today ann... Full story

Yahoo Finance • last year

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today anno... Full story

Yahoo Finance • last year

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander promoted to Chief Strategy Officer Ovid str... Full story

Yahoo Finance • last year

Ovid Therapeutics Added to Russell 3000® Index

NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders,... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

Ovid Therapeutics Inc. Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseases Long-term data supporting soticlestat safety, tolerability and seizure-reduction efficacy presen... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2 signaling pathway to accelerate a series of cli... Full story

Yahoo Finance • 2 years ago

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting

Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studiesSustained reduction in frequency of drop seizures among Lennox-Gastaut patients and convulsive seizures among Dravet patients... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a  biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today an... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future clinical trials has been achieved for OV350, one of several compounds from the Company’s KCC2 activator portfolioTakeda's guidance on soticlestat r... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders,... Full story

Yahoo Finance • 2 years ago

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal excitation, including epilepsiesTwo preclinical seizure models suggest that OV350 mitigates neuronal hyperex... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders,... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

Recognized epileptologist and medical affairs leader, Manoj Malhotra, M.D., joins as Chief Medical Officer Drug discovery and development scientist and soticlestat co-inventor, Toshiya Nishi, D.V.M., joins as Head of Epilepsy Research NEW... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders,... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other GABA-aminotransferase inhibitors Data from the NIH/NINDs Epilepsy Therapy Screening Program demon... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Drug (IND) application for OV329, its GABA-aminotransferase inhibitor The Company ended Q3 2022 with cash, cas... Full story